scispace - formally typeset
Journal ArticleDOI

Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.

Konstantinos Avgoustakis
- 30 Sep 2004 - 
- Vol. 1, Iss: 4, pp 321-333
TLDR
The ability of the PLA-Peg and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting.
Abstract
The preparation, properties and potential applications in drug delivery of biocompatible and biodegradable PLA-PEG and PLGA-PEG nanoparticles are discussed. PLA-PEG and PLGA-PEG nanoparticles have been produced by emulsification-solvent evaporation, solvent displacement and salting out methods. The nanoparticles can be stored as freeze-dried powders, but an adequate amount of a suitable lyoprotectant should be added prior lyophilisation to prevent nanoparticle aggregation and retain nanoparticle redispersibility. The nanoparticles have a core-shell structure with a PLA core and a PEG coating. Their basic colloidal properties and degradation depend on copolymer composition. The PLA-PEG and PLGA-PEG nanoparticles exhibit prolonged blood circulation following intravenous administration to animals. The composition of the nanoparticles determine their biodistribution properties, probably through its effects on the effectiveness of the PEG steric barrier and the size of the nanoparticles. The ability of the PLA-PEG and PLGA-PEG nanoparticles to evade rapid phagocytocis has extended the range of sites within the body that the nanoparticles can reach, which has significant implications with regard to their application in controlled drug delivery and targeting. The PLA-PEG and PLGA-PEG nanoparticles can be loaded with a variety of bioactive agents achieving satisfactory loading, especially in the case of hydrophobic drugs. The nanoparticles have been investigated for the treatment of infectious diseases and cancer, the intravenous and mucosal delivery of proteins, and oligonucleotide and gene delivery. The results have been encouraging and PLA-PEG and PLGA-PEG nanoparticle formulations, improving the therapeutic potential of both established and new drugs, may be expected to be available in the near future.

read more

Citations
More filters
Patent

Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia

TL;DR: In this paper, the authors provide compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.
Book ChapterDOI

Formulation of depot delivery systems

TL;DR: Depot delivery systems, also known as sustained-release systems, are parenteral formulations containing multiple doses of drug that, when introduced into the body, are designed to release the drug over a specified, often prolonged, period of time as mentioned in this paper.
Book ChapterDOI

Nanotechnological Approach for Design and Delivery of Phytopharmaceuticals

TL;DR: In this article, the challenges associated with the development of novel formulations and focus on the design and development of various nanocarriers like phytosomes, liposome, transfersomes, ethosomes, solid lipid nanoparticles, nanoemulsion, self-micro-emulsifying and nanoemultering system, and polymeric nanoparticle and microsphere and its future prospective.
Journal ArticleDOI

Formulation and evaluation of isorhamnetin loaded poly lactic-co-glycolic acid nanoparticles

TL;DR: It is concluded that the newly formulated NP drug delivery systems of isorhamnetin provided an insight into the therapeutic effectiveness of the designed formulation for the treatment of chemotherapy.
Related Papers (5)